PP.12.08] EVALUATION OF EFFICACY AND SAFETY OF AMOSARTAN IN PATIENTS WITH ESSENTIAL HYPERTENSION; 2-YEAR, NON-INTERVENTIONAL, MULTICENTER, RETROSPECTIVE OBSERVATIONAL STUDY

Abstract

Objective: Studies have shown that combination of amlodipine and losartan resulted in significantly greater decrease in BP compared with amlodipine or losartan monotherapy in patients with essential hypertension. Amosartan is the first ARB/CCB (losartan/amlodipine) combination to be made and used in Korea, yet the safety and efficacy of chronic use has not been addressed. The objective of this study was to determine the safety and efficacy of long term Amosartan use in patients with essential hypertension. Design and method: A non-interventional, multicenter, retrospective observational study was conducted on 1000 healthy subjects. Subjects were hypertensive patients administered with Amosartan for at least 2 years with no more than 10 consecutive weeks of withdrawal period, and the duration of Amosartan therapy being more than 80% of the total follow-up period. The change in SBP and DBP 2 years in relation to baseline was analyzed as visit-to-visit BP variability during Amosartan follow-up period. SBP and DBP was measured and charted in each visit. Results: The percentage of patients who reached target SBP and both target SBP and DBP increased with prolonged duration of Amosartan treatment. However, there were reductions in the percentage of patients who reached target DBP at 3 months and 6 months after Amosartan treatment compared to baseline. 90% of total patients reached target SBP at 24 months after Amosartan treatment compared to 51% at baseline. 94% of total patients reached target DBP at 24 months after Amosartan treatment compared to 90% at baseline. 86% of total patients reached both target SBP and DBP at 24 months after Amosartan treatment compared to 45% at baseline. The mean SBP and DBP were consistently lower than the baseline values during the entire follow-up period after Amosartan treatment. The reduction in SBP and DBP in comparison to baseline was greatest at both 18 and 24 months after Amosartan treatment. Conclusions: The results of this study indicate that the long-term administration of Amosartan is effective in reducing and maintaining target blood pressure in patients with essential hypertension.